ENAapplication/xmlftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR337/036/SRR33789436/SRR33789436_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR337/037/SRR33789437/SRR33789437_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR337/036/SRR33789436/SRR33789436_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR337/037/SRR33789437/SRR33789437_1.fastq.gzprimary200OKGenomicsInstitute for Cancer and Genomic Sciences, University of Birminghamhttps://www.ebi.ac.uk/ena/browser/view/PRJNA1271021Homo sapiensxref:PubMed:40593493Myelodisplastic syndromes are a oligoclonal disease starting at the level of the stem/progenitor compartment. We used ATACseq to determine changes in chromating landscape between MDS low and high risk samples. Overall design: ATAC-seq of CD34+ HSCPs from MDS patients before and after disease progressionENAfalseChromatin accessibility of hematopoietic stem/progenitor cells (HSPCs) derived from MDS patients before and after disease progressionChromatin accessibility of hematopoietic stem/progenitor cells (HSPCs) derived from MDS patients before and after disease progression2025-09-242025-06-04PRJNA1271021GSE298729960640593493